Related Experiment Video
Updated: May 9, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
The rs2233678 polymorphism in PIN1 promoter region reduced cancer risk: a meta-analysis
1Department of Oncology, Shanghai First People's Hospital Affiliated Shanghai Jiaotong University, Shanghai, China. liqisjt@126.com
Background:
Published evidence suggests that the rs2233678 (-842 G>C) polymorphism in the PIN1 (peptidyl-prolyl cis/trans somerase NIMA-interacting 1) promoter region may be associated with cancer risk; however, the conclusion is still inconclusive.
Methods:
We conducted a meta-analysis to determine whether -842 G>C polymorphism was associated with cancer risk. Odds ratio (OR) and 95% confidence intervals (95% CI) were used to assess the strength of association. Genotype distribution data and adjusted ORs were collected to calculate the pooled ORs. Meta-regression was conducted to detect the source of heterogeneity. Publication bias was evaluated by Egger's test and Begg's test.
Results:
A total of 11 eligible studies, including 9280 participants, were identified and analyzed. Overall, we found that carriers of the -842 C allele were associated with significantly decreased cancer risk (C vs. G, OR = 0.750, 95% CI: 0.639-0.880, P(heterogeneity )= 0.014, estimated by genotype distribution data; CC+GC vs. GG, OR = 0.668, 95% CI: 0.594-0.751, P(heterogeneity) = 0.638, estimated by adjusted ORs). No evidence of publication bias was observed. Meta-regression revealed that ethnicities (p = 0.021) and sample size (p = 0.02) but not sources of control (p = 0.069) were the source of heterogeneity.
Conclusion:
These results suggest that the PIN1 rs2233678 (-842 G>C) polymorphism significantly reduces cancer risk.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Principles of Pharmacogenetics: Types of Genetic Variants
Cancer Prevention
Some...
